Platform Group raises 2026 forecast to €1bn sales on acquisitions, segment growth

The Platform Group AG has increased its medium-term forecast for the 2026 financial year, projecting net sales of approximately €1.0 billion, up from the previous forecast of over €860 million. Adjusted EBITDA is now expected to be in the range of €70 million to €80 million, a considerable rise from the prior forecast of over €64 million. Gross merchandise volume (GMV) is also anticipated to increase to around €1.7 billion, surpassing the previous estimate of €1.6 billion, while the 2025 financial year forecast remains unchanged.

This revised outlook is primarily fueled by three majority acquisitions in the pharmaceutical sector, signed in September and October 2025. These include the Vienna-based Pharmosan Group, Brno-based Vamida mail-order pharmacy, and Cologne-based pharmaceutical training platform Apothekia, together expected to contribute over €130 million in sales by 2026. Consequently, the "Service & Retail Goods" segment will be renamed "Pharma & Service Goods."

Furthermore, The Platform Group has entered agreements to acquire two additional companies in the "Optics & Hearing" segment. These companies are projected to generate sales in the single-digit million range, with an EBITDA margin of approximately 24%. All transactions are expected to close by the end of 2025, pending approval from relevant antitrust authorities.